DE69536091D1 - Immunisierung durch Impfung von DNS Transkriptionseinheit - Google Patents
Immunisierung durch Impfung von DNS TranskriptionseinheitInfo
- Publication number
- DE69536091D1 DE69536091D1 DE69536091T DE69536091T DE69536091D1 DE 69536091 D1 DE69536091 D1 DE 69536091D1 DE 69536091 T DE69536091 T DE 69536091T DE 69536091 T DE69536091 T DE 69536091T DE 69536091 D1 DE69536091 D1 DE 69536091D1
- Authority
- DE
- Germany
- Prior art keywords
- vertebrate
- transcription unit
- dna transcription
- cell
- humoral
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000013518 transcription Methods 0.000 title abstract 3
- 230000035897 transcription Effects 0.000 title abstract 3
- 230000003053 immunization Effects 0.000 title abstract 2
- 238000002649 immunization Methods 0.000 title 1
- 238000002255 vaccination Methods 0.000 title 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 abstract 4
- 239000000427 antigen Substances 0.000 abstract 4
- 102000036639 antigens Human genes 0.000 abstract 4
- 108091007433 antigens Proteins 0.000 abstract 4
- 230000001404 mediated effect Effects 0.000 abstract 2
- 230000004044 response Effects 0.000 abstract 2
- 241000271566 Aves Species 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 230000006023 anti-tumor response Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000028996 humoral immune response Effects 0.000 abstract 1
- 230000021633 leukocyte mediated immunity Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000001717 pathogenic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/15—Reoviridae, e.g. calf diarrhea virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12311—Rotavirus, e.g. rotavirus A
- C12N2720/12322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12311—Rotavirus, e.g. rotavirus A
- C12N2720/12334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/11011—Alpharetrovirus, e.g. avian leucosis virus
- C12N2740/11041—Use of virus, viral particle or viral elements as a vector
- C12N2740/11043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/187,879 US6841381B1 (en) | 1992-03-23 | 1994-01-27 | Immunization by inoculation of DNA transcription unit |
Publications (1)
Publication Number | Publication Date |
---|---|
DE69536091D1 true DE69536091D1 (de) | 2010-09-09 |
Family
ID=22690873
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69536091T Expired - Lifetime DE69536091D1 (de) | 1994-01-27 | 1995-01-25 | Immunisierung durch Impfung von DNS Transkriptionseinheit |
Country Status (7)
Country | Link |
---|---|
EP (2) | EP0740704A1 (de) |
JP (2) | JP4050310B2 (de) |
AT (1) | ATE475668T1 (de) |
CA (1) | CA2181832C (de) |
DE (1) | DE69536091D1 (de) |
ES (1) | ES2348013T3 (de) |
WO (1) | WO1995020660A2 (de) |
Families Citing this family (81)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5643578A (en) | 1992-03-23 | 1997-07-01 | University Of Massachusetts Medical Center | Immunization by inoculation of DNA transcription unit |
US6165993A (en) * | 1992-03-23 | 2000-12-26 | University Of Massachusetts Medical Center | DNA vaccines against rotavirus infections |
US5620896A (en) * | 1992-03-23 | 1997-04-15 | University Of Massachusetts Medical Center | DNA vaccines against rotavirus infections |
US6127116A (en) * | 1995-08-29 | 2000-10-03 | Washington University | Functional DNA clone for hepatitis C virus (HCV) and uses thereof |
US6270795B1 (en) | 1995-11-09 | 2001-08-07 | Microbiological Research Authority | Method of making microencapsulated DNA for vaccination and gene therapy |
GB9709900D0 (en) * | 1997-05-15 | 1997-07-09 | Microbiological Res Authority | Microencapsulated DNA for vaccination and gene therapy |
ATE192334T1 (de) * | 1995-11-09 | 2000-05-15 | Microbiological Res Authority | Mikroverkapselte dna zur impfung und gentherapie |
US6723558B1 (en) | 1996-01-23 | 2004-04-20 | St. Jude Children's Research Hospital | Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses |
US5741492A (en) * | 1996-01-23 | 1998-04-21 | St. Jude Children's Research Hospital | Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses |
WO1997028265A1 (en) * | 1996-02-05 | 1997-08-07 | University Of Massachusetts Medical Center | Measles immunization by dna transcription unit inoculation |
IL125547A0 (en) * | 1996-02-22 | 1999-03-12 | Merck & Co Inc | Synthetic hiv genes |
US6534312B1 (en) | 1996-02-22 | 2003-03-18 | Merck & Co., Inc. | Vaccines comprising synthetic genes |
JP2000516445A (ja) * | 1996-06-21 | 2000-12-12 | メルク エンド カンパニー インコーポレーテッド | 合成遺伝子を含むワクチン |
AU3514197A (en) | 1996-07-03 | 1998-01-21 | Genetics Institute Inc. | Protease fmh-1, an ice/ced-like protease |
FR2751226B1 (fr) | 1996-07-19 | 1998-11-27 | Rhone Merieux | Formule de vaccin polynucleotidique contre les pathologies du cheval |
FR2751223B1 (fr) * | 1996-07-19 | 1998-12-04 | Rhone Merieux | Formule de vaccin polynucleotidique felin |
FR2751229B1 (fr) * | 1996-07-19 | 1998-11-27 | Rhone Merieux | Formule de vaccin polynucleotidique notamment contre la pathologie respiratoire des bovins |
FR2751228B1 (fr) | 1996-07-19 | 1998-11-20 | Rhone Merieux | Vaccin polynucleotidique bovin pour voie intradermique |
FR2751227B1 (fr) * | 1996-07-19 | 1998-11-27 | Rhone Merieux | Formule de vaccin polynucleotidique contre les pathologies canines, notamment les pathologies respiratoires et digestives |
FR2751224B1 (fr) * | 1996-07-19 | 1998-11-20 | Rhone Merieux | Formule de vaccin polynucleotidique contre les pathologies respiratoires et de reproduction des porcs |
FR2751225B1 (fr) * | 1996-07-19 | 1998-11-27 | Rhone Merieux | Formule de vaccin polynucleotidique aviaire |
US7294338B2 (en) | 1996-07-19 | 2007-11-13 | Merial | Polynucleotide vaccine formula against canine pathologies, in particular respiratory and digestive pathologies |
US5783567A (en) * | 1997-01-22 | 1998-07-21 | Pangaea Pharmaceuticals, Inc. | Microparticles for delivery of nucleic acid |
US6696291B2 (en) | 1997-02-07 | 2004-02-24 | Merck & Co., Inc. | Synthetic HIV gag genes |
CN1044092C (zh) | 1997-02-26 | 1999-07-14 | 上海医科大学 | 抗原-抗体-重组dna复合型疫苗 |
US7049428B1 (en) | 1998-03-04 | 2006-05-23 | Washington University | HCV variants |
US7338759B1 (en) | 1997-03-04 | 2008-03-04 | Washington University | HCV variants |
US6517843B1 (en) | 1999-08-31 | 2003-02-11 | Merial | Reduction of porcine circovirus-2 viral load with inactivated PCV-2 |
UA78180C2 (uk) | 1997-10-03 | 2007-03-15 | Меріаль | Кільцевий вірус свині типу ii, вакцини та діагностичні реагенти |
GB9810236D0 (en) | 1998-05-13 | 1998-07-08 | Microbiological Res Authority | Improvements relating to encapsulation of bioactive agents |
US6406719B1 (en) | 1998-05-13 | 2002-06-18 | Microbiological Research Authority | Encapsulation of bioactive agents |
EP1096957A1 (de) | 1998-06-18 | 2001-05-09 | Johns Hopkins University School of Medicine | Verfahren und reagentien zur intramuskulären zufuhr von nukleinsäuren |
US6916490B1 (en) | 1998-07-23 | 2005-07-12 | UAB Research Center | Controlled release of bioactive substances |
GB9818627D0 (en) | 1998-08-26 | 1998-10-21 | Glaxo Group Ltd | Improvements in dva vaccination |
US6881723B1 (en) | 1998-11-05 | 2005-04-19 | Powderject Vaccines, Inc. | Nucleic acid constructs |
US7022320B1 (en) | 1999-02-09 | 2006-04-04 | Powderject Vaccines, Inc. | Mycobacterium tuberculosis immunization |
US7196066B1 (en) | 1999-11-03 | 2007-03-27 | Powderject Vaccines, Inc. | DNA-vaccines based on constructs derived from the genomes of human and animal pathogens |
US7078388B2 (en) | 2000-01-21 | 2006-07-18 | Merial | DNA vaccines for farm animals, in particular bovines and porcines |
US6852705B2 (en) | 2000-01-21 | 2005-02-08 | Merial | DNA vaccines for farm animals, in particular bovines and porcines |
AUPS054702A0 (en) | 2002-02-14 | 2002-03-07 | Immunaid Pty Ltd | Cancer therapy |
US6783759B2 (en) | 2002-03-27 | 2004-08-31 | Trustees Of The University Of Pennsylvania | Compositions and methods for modulating variola virus |
US6982156B2 (en) | 2002-03-27 | 2006-01-03 | Trustees Of The University Of Pennsylvania | Compositions and methods modulating variola and vaccinia virus |
NZ546554A (en) | 2003-10-10 | 2009-04-30 | Powderject Vaccines Inc | Nucleic acid constructs |
BRPI0415533A (pt) | 2003-10-24 | 2006-12-26 | Immunaid Pty Ltd | método de terapia |
WO2005117964A2 (en) | 2004-05-27 | 2005-12-15 | Centocor, Inc. | Cynomolgus prostate specific antigen |
US20060121031A1 (en) | 2004-12-07 | 2006-06-08 | Mckenzie Brent S | Relay vaccine |
US8202967B2 (en) | 2006-10-27 | 2012-06-19 | Boehringer Ingelheim Vetmedica, Inc. | H5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use |
EP2164862B1 (de) | 2007-06-08 | 2015-07-22 | Australian Poultry CRC Pty Ltd | Das clostridient-toxin netb |
AU2008294074B2 (en) | 2007-08-30 | 2015-01-22 | Walter And Eliza Hall Institute Of Medical Research | Dendritic cell marker and uses thereof |
ES2548508T3 (es) | 2009-05-27 | 2015-10-19 | Biotempus Limited | Métodos de tratamiento de enfermedades |
AR078253A1 (es) | 2009-09-02 | 2011-10-26 | Boehringer Ingelheim Vetmed | Metodos para reducir la actividad antivirica en composiciones pcv-2 y composiciones pcv-2 con mejor inmunogenicidad |
RU2578420C2 (ru) | 2010-05-10 | 2016-03-27 | Эсенд Байофармасьютикалз Пти Лтд | Иммуностимулирующие и вакцинные композиции |
AR083533A1 (es) | 2010-10-22 | 2013-03-06 | Boehringer Ingelheim Vetmed | Proteinas de hemaglutinina 5 (h5) para el tratamiento y prevencion de las infecciones de gripe |
AR088028A1 (es) | 2011-08-15 | 2014-05-07 | Boehringer Ingelheim Vetmed | Proteinas h5, de h5n1 para un uso medicinal |
WO2013033092A2 (en) | 2011-09-03 | 2013-03-07 | Boehringer Ingelheim Vetmedica Gmbh | Streptococcus suis pilus antigens |
AU2012327878A1 (en) | 2011-10-28 | 2014-05-29 | Patrys Limited | PAT-LM1 epitopes and methods for using same |
ES2689878T3 (es) | 2013-02-21 | 2018-11-16 | Boehringer Ingelheim Vetmedica Gmbh | Proteínas H5 del virus de la gripe H5N1 para su uso como un medicamento |
CA2943816A1 (en) | 2014-04-03 | 2015-10-08 | Boehringer Ingelheim Vetmedica, Inc. | Porcine epidemic diarrhea virus vaccine |
WO2016000022A1 (en) | 2014-06-30 | 2016-01-07 | Murdoch Childrens Research Institute | Helicobacter therapeutic |
DK3344289T3 (da) | 2015-08-31 | 2020-04-14 | Boehringer Ingelheim Vetmedica Gmbh | Pestivirusvacciner mod medfødt tremor |
MX2018003173A (es) | 2015-09-16 | 2018-05-17 | Boehringer Ingelheim Vetmedica Inc | Vacunas de salmonella choleraesuis-salmonella typhimurium. |
BR112019005418A2 (pt) | 2016-09-20 | 2019-10-01 | Boehringer Ingelheim Vetmedica Gmbh | novos promotores |
UY37405A (es) | 2016-09-20 | 2018-03-23 | Boehringer Ingelheim Vetmedica Gmbh | Vectores de adenovirus canino |
KR102566066B1 (ko) | 2016-09-20 | 2023-08-16 | 베링거잉겔하임베트메디카게엠베하 | 신규한 돼지 인플루엔자 백신 |
US10619169B2 (en) | 2016-09-20 | 2020-04-14 | Boehringer Ingelheim Vetmedica Gmbh | EHV insertion site ORF70 |
EP3534945A1 (de) | 2016-11-03 | 2019-09-11 | Boehringer Ingelheim Vetmedica GmbH | Impfstoff gegen das schweineparvovirus |
CA3042584A1 (en) | 2016-11-03 | 2018-05-11 | Boehringer Ingelheim Vetmedica Gmbh | Vaccine against porcine parvovirus and porcine reproductive and respiratory syndrome virus and methods of production thereof |
EA201991762A1 (ru) | 2017-01-30 | 2020-01-23 | Бёрингер Ингельхайм Энимал Хелс Ю-Эс-Эй Инк. | Вакцины против коронавируса свиней |
US11179457B2 (en) | 2017-07-12 | 2021-11-23 | Boehringer Ingelheim Animal Health USA Inc. | Senecavirus a immunogenic compositions and methods thereof |
MY201967A (en) | 2017-09-23 | 2024-03-27 | Boehringer Ingelheim Pharma | Paramyxoviridae expression system |
WO2019092027A1 (en) | 2017-11-09 | 2019-05-16 | Boehringer Ingelheim Vetmedica Gmbh | Sapelovirus immunogenic compositions and uses thereof |
AU2019223768A1 (en) | 2018-02-23 | 2020-08-27 | Boehringer Ingelheim Animal Health USA Inc. | Recombinant viral vector systems expressing exogenous feline paramyxovirus genes and vaccines made therefrom |
CA3091960A1 (en) | 2018-03-19 | 2019-09-26 | Boehringer Ingelheim Vetmedica Gmbh | New ehv insertion site ul43 |
EP3768307A1 (de) | 2018-03-19 | 2021-01-27 | Boehringer Ingelheim Vetmedica GmbH | Neue ehv mit inaktiviertem ul18 und/oder ul8 |
JP7162072B2 (ja) | 2018-03-26 | 2022-10-27 | ベーリンガー インゲルハイム アニマル ヘルス ユーエスエイ インコーポレイテッド | 免疫原性組成物を製造する方法 |
CN112867506A (zh) | 2018-09-20 | 2021-05-28 | 勃林格殷格翰动物保健有限公司 | 抗猪流行性腹泻的鼻内载体疫苗 |
TW202027785A (zh) | 2018-09-20 | 2020-08-01 | 德商百靈佳殷格翰維美迪加股份有限公司 | 經修飾之pedv棘蛋白 |
EP4100420A1 (de) | 2020-02-06 | 2022-12-14 | Boehringer Ingelheim Vetmedica GmbH | Polypeptide zur detektion von anti-rhabdovirus-antikörpern |
EP4225776A1 (de) | 2020-10-05 | 2023-08-16 | Boehringer Ingelheim Vetmedica GmbH | Fusionsprotein zur impfung gegen rotavirus |
JP2023544403A (ja) | 2020-10-05 | 2023-10-23 | ベーリンガー インゲルハイム アニマル ヘルス ユーエスエイ インコーポレイテッド | サーコウイルス科カプシドタンパク質を含む融合タンパク質、及びそれから構成されるキメラウイルス様粒子 |
WO2023194913A1 (en) | 2022-04-05 | 2023-10-12 | Boehringer Ingelheim Vetmedica Gmbh | Immunogenic composition useful for vaccination against rotavirus |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU626288B2 (en) * | 1988-02-05 | 1992-07-30 | Commonwealth Scientific And Industrial Research Organisation | Gene expression system (particularly for rotavirus vp7 protein) involving a foreign signal peptide and optionally a transmembrane anchor sequence |
DK0465529T3 (da) * | 1989-03-21 | 1998-10-05 | Vical Inc | Ekspression af exogene polynukleotidsekvenser i et hvirveldyr |
AU3724093A (en) * | 1992-02-18 | 1993-09-03 | Smithkline Beecham Corporation | Vaccinal polypeptides |
US5643578A (en) * | 1992-03-23 | 1997-07-01 | University Of Massachusetts Medical Center | Immunization by inoculation of DNA transcription unit |
ES2242954T3 (es) | 1992-03-11 | 2005-11-16 | Powderject Vaccines, Inc. | Vacuna genetica para el virus de la inmunodeficiencia. |
WO1993025235A1 (en) | 1992-06-09 | 1993-12-23 | President And Fellows Of Harvard College | Aids therapeutics based on hiv-2 vpx peptides |
-
1995
- 1995-01-25 AT AT01202355T patent/ATE475668T1/de not_active IP Right Cessation
- 1995-01-25 EP EP95908672A patent/EP0740704A1/de not_active Withdrawn
- 1995-01-25 CA CA2181832A patent/CA2181832C/en not_active Expired - Fee Related
- 1995-01-25 WO PCT/US1995/000997 patent/WO1995020660A2/en not_active Application Discontinuation
- 1995-01-25 EP EP01202355A patent/EP1170368B1/de not_active Expired - Lifetime
- 1995-01-25 ES ES01202355T patent/ES2348013T3/es not_active Expired - Lifetime
- 1995-01-25 JP JP52014295A patent/JP4050310B2/ja not_active Expired - Fee Related
- 1995-01-25 DE DE69536091T patent/DE69536091D1/de not_active Expired - Lifetime
-
2006
- 2006-08-17 JP JP2006222713A patent/JP2006316072A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
ES2348013T3 (es) | 2010-11-26 |
EP1170368B1 (de) | 2010-07-28 |
JP2006316072A (ja) | 2006-11-24 |
CA2181832A1 (en) | 1995-08-03 |
EP0740704A1 (de) | 1996-11-06 |
WO1995020660A2 (en) | 1995-08-03 |
JPH09508622A (ja) | 1997-09-02 |
JP4050310B2 (ja) | 2008-02-20 |
ATE475668T1 (de) | 2010-08-15 |
CA2181832C (en) | 2012-11-27 |
EP1170368A3 (de) | 2004-05-12 |
WO1995020660A3 (en) | 1995-12-21 |
EP1170368A2 (de) | 2002-01-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE475668T1 (de) | Immunisierung durch impfung von dns transkriptionseinheit | |
CA2132836A1 (en) | Immunization by inoculation of dna transcription unit | |
DE69929444D1 (de) | Cpg-zusammensetzungen, saponin-adjuvantien und verfahren zu deren verwendung | |
NO963508L (no) | Urease-basert vaksine og behandling av Helicobacter-infeksjon | |
PT840791E (pt) | Desenvolvimento de respostas imunitarias para antigenios especificos da prostata (psa) | |
FI953608A (fi) | Rokoteyhdisteet ja menetelmä immuunireaktion aikaansaamiseksi limakalvossa järjestelmällisellä rokottamisella | |
DK1355930T3 (da) | Fremgangsmåde til identifikation, isolering og fremstilling af antigener mod et specifikt patogen | |
ATE292641T1 (de) | Mucin-mannan-konjugate und ihre immunotherapeutische anwendung | |
ATE318899T1 (de) | Fusionsproteine, die stressproteine beinhalten, zum hervorrufen einer immunantwort | |
IS4518A (is) | Nýtt lyfjaform fyrir bóluefni | |
ES2177927T3 (es) | Composicion para provocar una reaccion inmunologica a un determinante antigenico no proteinico. | |
BR0111834A (pt) | Composições adjuvante e imunogênica, e, método para eliciar uma resposta imune a um antìgeno | |
NO954318D0 (no) | Immunogent preparat av OspC-antigenvaksiner for forhindring og behandling av Lymesykdom, samt rekombinante fremgangsmåter for fremstilling av slike antigener | |
ATE149569T1 (de) | Verfahren zur herstellung von impfstoffen oder toxoiden | |
MX9301736A (es) | Vacuna de bacterina-toxoide de pasteurella haemolytica tipo a-1. | |
WO2001035993A3 (en) | Compositions and methods for stimulating an immune response against infectious agents | |
DE69615537T2 (de) | Helicobacter pylori antigen | |
ATE353226T1 (de) | Adjuvanszusammensetzung enthaltend fha oder ein fha-fragment in freier form | |
EP1502602A3 (de) | Verfahren zur therapeutischen Impfung |